Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon alfa-2b in HBeAg-positive chronic hepatitis B
NCT02973646Phase 4Unknown
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Jan 2016
- Primary completion
- Dec 2018
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Good Virologic Response at 24 weeks. Status: unknown.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02973646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02973646.